Tianjin Tianyao Pharmaceutical (600488) Growth Maintained Steady with Limited Impact from Financial Crisis --- Neutral

  • Contributor:TX Investment Consulting
  • Date:Apr 22, 2009
  • Pages:5pages
  • Price:$80.00
  • File Type: Adobe Acrobat Reader®
Download Free Adobe Acrobat Reader®

Research Reports Premium Services

-Get the full report for $80.00

-The financial products you have ordered will be sent to   you within 24 hours via e-mail.

Excerpts:

In Q1 2009, the company reported operating revenue of Rmb211mn (+6.6% yoy or -3.3% qoq), operating profit of Rmb11.07mn (+3.5% yoy or +79.0% qoq), net profit attributable to parent of Rmb9.66mn (+13.4% yoy or -0.9% qoq) and basic EPS of Rmb0.018.

 

Earning forecast and rating: We maintain our forecast of the company and predict its 2009-2010E EPS to be Rmb0.11 and Rmb0.13 respectively, representing dynamic P/E ratio at 73x and 60x based on current share price of Rmb8.04; “Neutral” rating is temporarily given.

 

Potential risks: 1) Uncertainty in operation of new production base.


SSL